ライフサイエンスコーパス: control subject

1 s) and hippocampus (83 schizophrenia and 187 control subjects).

2 ol subject (final cohort, 11 patients and 11 control subjects).

3 Resource Company study (94 patients and 100 control subjects).

4 4,545 or 7,397 T2D case and 38,994 or 71,604 control subjects).

5 with suspected early-stage lung malignancy (control subjects).

6 individuals with schizophrenia compared with control subjects.

7 out on 1546 patients with psoriasis and 1526 control subjects.

8 ith CHD have not been compared with those in control subjects.

9 from 1156 Parkinson's disease cases and 1679 control subjects.

10 sing 700 patients with EoE and 801 community control subjects.

11 individuals (N = 2,274,713) were defined as control subjects.

12 iatum in pathological gamblers compared with control subjects.

13 case patients were age and sex matched with control subjects.

14 toward lower entropy (P = .07) compared with control subjects.

15 e and after bariatric surgery and in 10 lean control subjects.

16 gens in DOCK8-deficient patients and healthy control subjects.

17 rval, 19.26-25.12) in patients with CHD than control subjects.

18 gher prevalence of LGE compared with healthy control subjects.

19 lood from 25 RD-SG, 11 RD-nonSG, 3 RF and 10 control subjects.

20 RT-PCR analysis of cohorts of 24 T1DM and 24 control subjects.

21 m in 13 pathological gamblers and 15 healthy control subjects.

22 methods for discrimination of patients from control subjects.

23 s with diabetes without stroke and 30 normal control subjects.

24 ients with mild-to-severe asthma and healthy control subjects.

25 s using 412 nonatopic and 868 atopic disease control subjects.

26 entropy and MPP compared with normal-weight control subjects.

27 al memory-disordered patients and 14 healthy control subjects.

28 obese HFpEF, those with nonobese HFpEF, and control subjects.

29 ter) from 50 former smokers with COPD and 39 control subjects.

30 thylation levels similar to those of healthy control subjects.

31 AE, 22 patients with sporadic U-HAE, and 200 control subjects.

32 and OCD (structural MRI: 928; fMRI: 247) and control subjects.

33 computed tomography (CT) served as positive control subjects.

34 atients with NIDCM from age- and sex-matched control subjects.

35 ate, and severe asthma and nonatopic healthy control subjects.

36 idence of inflammation compared with healthy control subjects.

37 bipolar disorder) and 50 age-matched healthy control subjects.

38 recurrent pregnancy loss when compared with control subjects.

39 gly connected to one another than in healthy control subjects.

40 f 20 patients with IS and 20 matched healthy control subjects.

41 pirometry were recorded in 186 cases and 160 control subjects.

42 h CM-FPIES, results were similar to those in control subjects.

43 differ between patients with FEP and healthy control subjects.

44 ively, for distinguishing cases from no-COPD control subjects.

45 ignificantly different compared with healthy control subjects.

46 IL-13 and IL-31) was similar to that seen in control subjects.

47 ral pole were found in NTSCUs versus healthy control subjects.

48 wood users assigned to ethanol with firewood control subjects.

49 otonin transporter (SERT) density in healthy control subjects.

50 87 participants with morphea and 26 healthy control subjects.

51 tabolic profiles similar to those of healthy control subjects.

52 iglustat treated), heterozygote, and healthy control subjects.

53 1,493 people who presented with MI and 3,232 control subjects.

54 ary analysis, we compared ethanol users with control subjects.

55 evation myocardial infarction (STEMI) and 42 control subjects.

56 derate asthma (MMAs), and healthy nonsmoking control subjects.

57 , and 37 age-, sex-, and comorbidity-matched control subjects.

58 sive and in situ groups with those of 60,166 control subjects.

59 ation in circulating monocytes compared with control subjects.

60 12-month intervals) from 147 UHR and healthy control subjects.

61 with 195 unresolved case subjects and 6,905 control subjects.

62 iagnosis of aGVHD compared with time-matched control subjects.

63 n chronic schizophrenia patients and healthy control subjects.

64 in samples from OAs compared with those from control subjects.

65 spectively enrolled together with 20 matched control subjects.

66 pathological gamblers compared with healthy control subjects.

67 icant experiences were compared with matched control subjects.

68 ositive predictive values for both cases and control subjects.

69 longitudinal peak was reduced compared with control subjects.

70 ic activity in key brain areas compared with control subjects.

71 ong exposed subjects compared with unexposed control subjects.

72 th purified IgE of patients with CSU but not control subjects.

73 ld-to-moderate disease compared with healthy control subjects.

74 ls were also sporadically found in islets of control subjects.

75 e comparisons) and 57 age-matched GBCA-naive control subjects.

76 nonsmoking T2DM patients than in nonsmoking control subjects.

77 h Gram-negative sepsis compared with healthy control subjects.

78 total cell-free circulating RNA from healthy control subjects.

79 ume was larger in the MDD cohort compared to control subjects.

80 with ET and 18 age- and sex-matched healthy control subjects.

81 67.8% for differentiating cases from no-COPD control subjects.

82 and transfected cells from both patients and control subjects.

83 m samples from lymphoma patients and healthy control subjects.

84 facilities, and using nonleukemia cancers as control subjects.

85 ssue was obtained from patients with CRS and control subjects.

86 chizophrenia patients and 26 matched healthy control subjects.

87 and less Bacteroidetes compared with healthy control subjects.

88 nts with CVID compared with those of healthy control subjects.

89 in patients with CSU that were not found in control subjects.

90 head movement, respectively, than did young control subjects (1.79 mm +/- 0.77) (P < .001).

91 tients were compared with general population control subjects (1:10 ratio).

92 ears) and 36 normotensive previously healthy control subjects (14 men; median age, 43 years; interqua

93 re, 55 and 65, respectively) and age-matched control subjects (15 children and 27 adults).

94 In vivo DT-CMR was performed in 19 control subjects, 19 DCM, and 13 HCM patients.

95 lower in patients with pediatric AD than in control subjects (24% vs 33%, P = .04), whereas CD3(+) T

96 more common in pNF subjects than in healthy control subjects (4 versus 1).

97 e randomly selected and were matched with 27 control subjects (53 carotids without IPH) to undergo a

98 nts (51.6% men) with CHD and 219 816 matched control subjects, 654 and 328 developed AF, respectively

99 uch better," and none felt "much worse." One control subject (8%) and one storytelling subject (6%) s

100 said that the study was burdensome, and one control subject (8%) wished they had not participated.

101 years, AHI:11.1 +/- 5.9 events/hr), and 200 control subjects (84 male, 8.2 +/- 2.0 years), 191 of wh

102 improved SN and SP for all cases versus all control subjects (89.7% and 78.1%, respectively) and for

103 spectively) and for all cases versus no-COPD control subjects (89.7% and 93.1%, respectively).

104 equivalent in identifying sera from negative-control subjects (99% and 100% specificity, respectively

105 HFOV patients versus 288 of 767 (37.6%) for control subjects (adjusted odds ratio, 1.17; 95% confide

106 bar punctures were performed in GWI, CFS and control subjects after (i) overnight rest (nonexercise)

107 em DLPFC data set (182 schizophrenia and 212 control subjects), although notably at least five of the

108 Results Similar to the results in control subjects, analysis of the 60 patients showed exc

109 New lesion volume was 178.0 mm(3) in control subjects and 102.8 mm(3) in the device arm (p =

110 ytelling, 14 of 14 (100%) and 13 of 14 (94%) control subjects and 16 of 18 (89%) and 17 of 18 (94%) s

111 Strokes at 30 days were 9.1% in control subjects and 5.6% in patients with devices (p =

112 A total of 22 hypertensive control subjects and 98 HFpEF subjects underwent hemodyn

113 We recruited 80 healthy control subjects and AD patients with and without FLG mu

114 eeking cocaine users (NTSCUs) and 67 healthy control subjects and an independent treatment-completed

115 isolated from patients with PAH and healthy control subjects and assessed for expression of MCUC sub

116 ntral rich club (RC) system relative to both control subjects and BD offspring.

117 s assigned to the intervention with kerosene control subjects and compared baseline firewood users as

118 h neurodegenerative disease and 4351 healthy control subjects and found p.A152T associated with signi

119 ificant difference was found between healthy control subjects and glaucoma patients in the mean rate

120 g plasma levels of peptide YY and ghrelin in control subjects and in critically ill patients, during

121 Eight hundred fifty cases and 926 hyper-control subjects and more than 7.8 million genotyped and

122 reduced in MS patients compared with healthy control subjects and other inflammatory neurological dis

123 train parameters were compared first between control subjects and patients and then according to atri

124 d 0.89, respectively) for separation between control subjects and patients when compared with the sta

125 entiation and monocyte activation in healthy control subjects and patients with autoinflammatory synd

126 0.25) Neurocognitive function was similar in control subjects and patients with devices, but there wa

127 nd miR-143-3p differentiated between healthy control subjects and patients with IS with an area under

128 network alterations when compared with both control subjects and patients with PD without MCI (range

129 city measurements in the pulmonary artery in control subjects and patients with pulmonary arterial hy

130 rabbing nonintegrin in macrophages from both control subjects and patients.

131 prolonged in SCI participants compared with control subjects and stimulation was provided approximat

132 ctivity in patients with MS as compared with control subjects and suggest that the decreased connecti

133 white matter structure between patients and control subjects and tested associations with age, sympt

134 th fCCM was compared with that in unaffected control subjects and those with sporadic CCM by using th

135 ents with anorexia nervosa and normal-weight control subjects and to determine body composition predi

136 al cortex (DLPFC) (144 schizophrenia and 196 control subjects) and hippocampus (83 schizophrenia and

137 K-HiTDiP] study (113 patients and 57 healthy control subjects) and the Janssen-Brain Resource Company

138 plication (200 patients with IS, 100 healthy control subjects), and in 72 patients with transient isc

139 to compare ADCs between patient subsets and control subjects, and a receiver operating characteristi

140 of 44.4% for differentiating cases from all control subjects, and an SN of 95.7% and an SP of 67.8%

141 on marker Ki67 or the ductal marker CK19 vs. control subjects, and islet inflammatory cell infiltrate

142 alyzed in healthy adolescents, Mtb-unexposed control subjects, and patients with pulmonary tuberculos

143 ather than in the absence of, migraine or in control subjects, and that the association between light

144 ectively, for differentiating cases from all control subjects, and they were 88.0% and 90.8%, respect

145 Survivors were less active than control subjects, as demonstrated by a step count differ

146 eflections in HFpEF were similar to those in control subjects at rest.

147 ntensity (SI) relative to that in GBCA-naive control subjects at unenhanced T1-weighted magnetic reso

148 otivated, and therefore less successful than control subjects, at avoiding what they preferred not to

149 t is, [(11)C]ABP688 binding) in both MDD and control subjects (average of 14+/-9% and 19+/-22%, respe

150 l-Making Test, Part B, time spent in healthy control subjects but not in chronic schizophrenia patien

151 rier integrity in ALI cultures of HBECs from control subjects but not in HBECs from asthmatic patient

152 icantly higher in patients with CeVD than in control subjects, but differences were less with greater

153 bjects and 54 age- and sex- matched nonobese control subjects by MRI and analyzed the T2 hyperintensi

154 features were compared between patients and control subjects by using the Wilcoxon signed-rank test,

155 methotrexate and eight untreated age-matched control subjects by using Wilcoxon rank-sum tests.

156 subgroup B contained 81% of patients; 50% of control subjects; chi(2) = 8.6, p = .003) and default mo

157 th current PTSD compared with trauma-exposed control subjects (Cohen's d = -0.17, p = .00054), and sm

158 d significantly greater E2A in diastole than control subjects did (48 degrees ; p < 0.001) with impai

159 e subjects with pulmonary fibrosis and 4,141 control subjects drawn from among a set of individuals o

160 In healthy human control subjects, E2A increased from diastole (18 degree

161 Comparing patients with EoE and nonatopic control subjects, EoE associated strongly with IL-4/kine

162 paring patients with EoE with atopic disease control subjects, EoE associated strongly with ST2 (P =

163 currence and 11 had an identifiable matching control subject (final cohort, 11 patients and 11 contro

164 ents with Hymenoptera allergy and 76 healthy control subjects for comparison.

165 g a total sample of 22,158 cases and 133,749 control subjects for subsetting.

166 mass index <30 kg/m(2); n=96), and nonobese control subjects free of HF (n=71) underwent detailed cl

167 For TBV, 2523 patients and 7880 control subjects from 31 studies were included.

168 a were combined from 3024 MDD cases and 2741 control subjects from nine cohorts contributing to the M

169 ort of 183 acute melioidosis patients and 21 control subjects from Northeast Thailand and studied imm

170 a GWAS in 2,499 T2D case subjects and 5,247 control subjects from six Hispanic/Latino background gro

171 he cerebellar volume of 328 patients and 353 control subjects from the ABIDE project.

172 2 diabetes-affected case subjects and 5,765 control subjects from the CARe cohort, downsampled to in

173 biospecimens from 909 AA and 847 EA healthy control subjects from the Carolina Breast Cancer Study (

174 d validated to recruit cases with asthma and control subjects from the Electronic Medical Records and

175 tched by birth year, sex, and county with 10 control subjects from the Total Population Register in S

176 had 11C-Pittsburgh compound B and 10 healthy control subjects had 11C-(R)-PK11195 positron emission t

177 Twelve age-matched healthy control subjects had 11C-Pittsburgh compound B and 10 he

178 Control subjects had similarly shorter reaction times du

179 A second asthma group and control subjects had symptom scores, spirometry, and bro

180 usted models, TD/CTD patients, compared with control subjects, had an increased risk of both dying by

181 edication-free patients with MDD and healthy control subjects (HC) completed baseline rs-fcMRI.

182 ore narrowly but more intensely than healthy control subjects (HCS).

183 with schizophrenia (SCH) relative to healthy control subjects (HCs).

184 As compared to control subjects, higher leptin was associated with the

185 APS-IgG and SLE/APS- IgG compared to healthy control subjects' IgG, and FXa alone.

186 line in the EC users or between EC users and control subjects in any of the health outcomes investiga

187 tes of depression and possible resilience in control subjects in spite of biological overlap.

188 fferentially expressed compared with that of control subjects, independent of source of infection, wi

189 r function, were DA in patients with SAR and control subjects, irrespective of season.

190 In control subjects, magnetization transfer ratio was highe

191 ungs was lower for patients with CF than for control subjects (mean +/- standard deviation, 0.09 mL/m

192 an age, 56.41 +/- 2.78 years), and 12 normal control subjects (mean age, 55.67 +/- 3.08 years) with 3

193 abetes, or inflammatory conditions and in 14 control subjects (mean age: 60+/-11 years, mean eGFR: 86

194 n CLAD patients did not differ from those in control subjects (median number of LVs per bronchiole: 4

195 ratios were significantly different between control subjects (medians of 1.016 and 1.034, respective

196 patients with IS compared with both healthy control subjects (miR-125a-5p [1.8-fold; P=1.5x10(-6)],

197 adult atopic asthmatic patients (n = 12) and control subjects (n = 12).

198 In children with OSAS (n = 11) and control subjects (n = 12; age and sex matched), we perfo

199 s (n = 1539) with a DSM-IV MDD diagnosis and control subjects (n = 1792) were from two large cohort s

200 ompared their performance to matched healthy control subjects (n = 18), in behavioural tasks and in a

201 alized anxiety disorder (n = 24) and healthy control subjects (n = 20), patients with post-traumatic

202 logical anxiety (n = 25) and matched healthy control subjects (n = 23) completed a gambling task feat

203 iquid biopsies were collected from 2 groups: control subjects (n = 3) undergoing pars plana vitrectom

204 istent atopic asthma (n = 36) versus healthy control subjects (n = 36).

205 ) or BD (BD offspring; N = 60) and community control subjects (n = 39).

206 gnosed type 1 diabetes (n = 654) and healthy control subjects (n = 605) were analyzed in radiobinding

207 rum samples from patients with OA (n = 273), control subjects (n = 76) and patients with rheumatoid a

208 pathic or heritable PAH (n=365) from healthy control subjects (n=121) after correction for multiple t

209 =38), MCI with AD profile (n=20) and healthy control subjects (n=20).

210 use, as well as from psychiatrically healthy control subjects (N=26).

211 SD (N=19), or no PTSD (referred to as trauma control subjects) (N=17).

212 nia, N=51; psychosis risk, N=39; and healthy control subjects, N=53), the authors conducted a connect

213 ut DPN (eight men, 12 women), and 20 healthy control subjects (nine men, 11 women).

214 onal (PN) biopsies of psoriasis patients and control subjects (NN).

215 ue fibrocytes were not increased compared to control subjects nor were blood fibrocytes associated wi

216 In normal control subjects, Nt of SST-IR neurons varied according

217 Compared with those with nonobese HFpEF and control subjects, obese patients with HFpEF displayed wo

218 iation data from 26,676 T2D case and 132,532 control subjects of European ancestry after imputation u

219 dies than sera from patients with CRSwNP and control subjects (P < .0001).

220 CMV DNA in 41.5% of asthmatics and 13.3% of control subjects (P < .001).

221 ts with mitral regurgitation than in healthy control subjects (P < .001).

222 compared with UT of patients with CRSsNP and control subjects (P < .05) and correlated with levels of

223 m asthmatic patients compared with that from control subjects (P < .05).

224 ients with CRSwNP, patients with CRSsNP, and control subjects (P < .05).

225 ut not Glx, were significantly lower than in control subjects (P < 0.0002).

226 higher in both patient groups compared with control subjects (P < 0.05).

227 knowledge, for the first time, compared with control subjects (p < 0.05).

228 ls of IL-12p70 were greater in patients than control subjects (P = .0001), especially in patients wit

229 ficantly different between ethanol users and control subjects (P = 0.040); systolic blood pressure (S

230 in MMD and atherothrombotic stroke group or control subjects (P = 0.244).

231 Relative to control subjects, patients had significantly smaller HCV

232 When compared with matched control subjects, patients with DCIS recurrence exhibite

233 or cortices isolated from post-mortem normal control subjects, patients with familial ALS (fALS), spo

234 Relative to control subjects, patients with PD and MCI had a large b

235 Older control subjects, patients with PD, and subjects with MC

236 ol study of 376 IA case subjects and up to 3 control subjects per case subject.

237 Relative to trauma control subjects, PTSD patients showed stronger conditio

238 atio with age was observed only in pediatric control subjects (r = -0.48, P = .07).

239 2 receptor binding in the dorsal striatum of control subjects (R(2)=0.31, p<0.05) that was not presen

240 ar (containing 14 mg Fe)/d for 90 d, whereas control subjects received nothing.

241 In control subjects, regions showing highest connectivity t

242 udy using hospital-based cases (n = 127) and control subjects representative of the hospital catchmen

243 Control subjects responded to a startle stimulus similar

244 ulmonary arterial hypertension compared with control subjects showed a similar reduction in adhesion,

245 PPU subjects when compared with control subjects showed increased activation of ventral

246 d with both subjects with nonobese HFpEF and control subjects, subjects with obese HFpEF displayed in

247 ndex increased with age in patients, but not control subjects, suggesting accelerated effects of whit

248 last visit, mean DBP was 2.8 mm Hg higher in control subjects than in ethanol users (3.6 mm Hg greate

249 than in ethanol users (3.6 mm Hg greater in control subjects than in ethanol users among preinterven

250 light and positive emotions was stronger in control subjects than migraineurs.

251 Among control subjects, the 3 MTTT protocols were similarly sp

252 ts with Alzheimer's disease and five healthy control subjects to analyse the presence of phosphorylat

253 cise in subjects with HFpEF and hypertensive control subjects to examine their relationships to cardi

254 romic ASD sharing common behaviors and three control subjects, two clones each.

255 hasia, 6 age-matched patients with AD, and 6 control subjects underwent (18)F-flortaucipir PET and MR

256 s with relapsing-remitting MS and 20 healthy control subjects underwent a 3-T resting-state functiona

257 y-four patients with epilepsy and 16 healthy control subjects underwent an electroencephalography-cor

258 Patients with stable asthma and healthy control subjects underwent spirometry, methacholine chal

259 d and lung ILC2s from asthmatic patients and control subjects using flow cytometry and ELISA.

260 dized mean difference in TBV between LLD and control subjects was -0.10 (95% confidence interval, -0.

261 ence was 14 months, and median follow-up for control subjects was 102 months.

262 patients with atopic dermatitis and healthy control subjects was analyzed with flow cytometry.

263 d from plasma-derived EXOs of 12 T1DM and 12 control subjects was hybridized onto Nanostring human v2

264 54 with MCI, 116 without MCI) and 41 healthy control subjects was obtained by using deterministic dif

265 cases) and 20 deep-epithelium swabs (matched control subjects) was sequenced for the V1-V3 region usi

266 n 17 patients and 10 age-matched non-smoking control subjects we examined brachial artery flow-mediat

267 5 patients with chronic heart failure and 25 control subjects, we examined spontaneous oscillations i

268 Studying migraineurs and control subjects, we found that lights triggered more ch

269 Control subjects were 55 age-matched (+/- 2 years) girls

270 mean differences (Hedges' g) between LLD and control subjects were calculated from crude or adjusted

271 omen with anorexia nervosa and normal-weight control subjects were compared by using the Student t te

272 c >7.5%) and 24 age- and sex-matched healthy control subjects were consecutively enrolled.

273 preintervention kerosene users), and 6.4% of control subjects were hypertensive (SBP >/=140 and/or DB

274 Population-based community control subjects were identified from a separate CCHMC r

275 from 453 patients with NIDCM and 150 healthy control subjects were included between 2005 and 2013 and

276 Age-matched nonasthmatic control subjects were included to measure age-related in

277 Mothers of 127 cases and 121 control subjects were included.

278 mmatory differences between aged and younger control subjects were observed.

279 Control subjects were persons with no COPD or with mild

280 wenty-eight patients with CSM and 10 healthy control subjects were prospectively recruited and underw

281 agnosed Parkinson disease and 20 age-matched control subjects were recruited.

282 ine participants (39 patients with PD and 30 control subjects) were investigated with neuromelanin-se

283 ys) in the entire study population including control subjects, while no significant correlation was o

284 suffered from major depressive disorder and control subjects who had died from other causes.

285 breast cancer and 274 age- and race-matched control subjects who underwent screening FFDM during 200

286 first nonfatal MI and 2055 population-based control subjects who were living in Costa Rica to examin

287 rmed in pediatric and adult asthma cases and control subjects with European American and African Amer

288 ode psychosis as well as age-matched healthy control subjects with magnetic resonance spectroscopy (M

289 iability and DeltaSUVr were minimal in Abeta control subjects with no specific flortaucipir F 18 upta

290 han in convalescent samples (P </= .002) and control subjects with venom allergy (P < .0001).

291 ally regulated between patients with SAR and control subjects, with inverse abundance dynamics during

292 revious diagnosis of CIN3 and 89,018 matched control subjects without a history of CIN3.

293 rs; 27 females) as compared with age-matched control subjects without diabetes (n = 26; mean age = 7.

294 in young children with T1D as compared with control subjects without diabetes.

295 n pancreatic islets from donors with T2D and control subjects without diabetes.

296 2 diabetes had increased Mll1 compared with control subjects without diabetes.

297 (+) CD4(+) T cells compared with HLA-matched control subjects without diabetes.

298 were compared with 20 Achilles tendons in 10 control subjects without FH (two men, eight women; mean

299 mmunity-acquired pneumonia (n = 126), and of control subjects without sepsis (n = 10).

300 Relative to control subjects, youths reporting psychotic-like experi